

Formulary Changes Effective October 1, 2025					
CMS Formulary ID	Effective Date	Drug Name	Change Description	Reason Description	Alternate Drugs and Tier
25250	10/1/2025	FYCOMPA 6 MG ORAL TABLET	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	PERAMPANEL 6 MG ORAL TABLET-5
25250	10/1/2025	FYCOMPA 12 MG ORAL TABLET	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	PERAMPANEL 12 MG ORAL TABLET-5
25250	10/1/2025	FYCOMPA 10 MG ORAL TABLET	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	PERAMPANEL 10 MG ORAL TABLET-5
25250	10/1/2025	FYCOMPA 8 MG ORAL TABLET	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	PERAMPANEL 8 MG ORAL TABLET-5
25250	10/1/2025	FYCOMPA 4 MG ORAL TABLET	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	PERAMPANEL 4 MG ORAL TABLET-5
25250	10/1/2025	JYNARQUE 15 MG ORAL TABLET	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	TOLVAPTAN 15 MG ORAL TABLET-5
25250	10/1/2025	ENTRESTO 97MG-103MG ORAL TABLET	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	SACUBITRIL-VALSARTAN 97MG-103MG ORAL TABLET-3
25250	10/1/2025	ENTRESTO 49 MG-51MG ORAL TABLET	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	SACUBITRIL-VALSARTAN 49 MG-51MG ORAL TABLET-3
25250	10/1/2025	ENTRESTO 24 MG-26MG ORAL TABLET	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	SACUBITRIL-VALSARTAN 24 MG-26MG ORAL TABLET-3
25250	8/30/2025	IXCHIQ 1000 TCID INTRAMUSC. VIAL	REMOVAL DUE TO FDA MANDATED MARKET WITHDRAWAL	REMOVAL OF DRUG FROM FORMULARY DUE TO FDA MANDATED MARKET WITHDRAWAL	
25250	10/1/2025	JYNARQUE 30 MG ORAL TABLET	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	TOLVAPTAN 30 MG ORAL TABLET-5
25250	10/1/2025	FYCOMPA 2 MG ORAL TABLET	BRAND DELETION, ADD FRF GENERIC	REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT	PERAMPANEL 2 MG ORAL TABLET-4